Tafenoquine Combinations for Improved Radical Cure Efficacy of Plasmodium Vivax

Inclusion Criteria: * Participants who meet all of the following criteria may participate in the study: * Thai or non-Thai, male or non-pregnant/non-lactating female, aged at least 18 years * Willingness to participate in the study and provides signed written informed consent form * Have P. vivax malaria mono-infection as determined by blood smear, with a parasitemia range of 100-400,000 parasites/microliter * Have normal (non-deficient or \>70% activity) G6PD phenotype as measured by quantitative spectrophotometry * Agree to not seek outside medical care prior to contacting the WRAIR-AFRIMS study team if a fever develops during study participation (approximately 180 days), unless emergency medical care is required Exclusion Criteria: * Participants meeting any of the following criteria will be excluded from this study: * Have an allergic reaction to any of the study drugs or components (AL,TQ, artemisinins, PPQ or CQ) * History of anti-malarial drug use within the past 14 days (28 days for mefloquine or PPQ) * On screening EKG, found to have a QTcF of greater than 450 milliseconds (ms) (470 ms for females) * History of sudden cardiac death in an immediate family member, or personal history of known symptomatic coronary artery disease or arrhythmias * Acute or chronic, clinically significant, pulmonary, cardiovascular, hepatic, neurologic, or renal functional abnormality, as determined by history, physical examination, and laboratory evaluation; speci…